Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -522.73% | -365.47% | -111.08% | 117.50% | -369.53% |
| Total Depreciation and Amortization | 4.02% | 123.19% | -576.98% | -64.67% | 67.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.08% | -58.74% | 538.16% | -85.67% | 334.64% |
| Change in Net Operating Assets | -238.58% | 21.44% | 35.17% | 141.75% | -1,127.79% |
| Cash from Operations | -182.17% | 19.00% | 8.69% | 444.95% | -124.77% |
| Capital Expenditure | -73.37% | 51.57% | -60.14% | -95.42% | 37.36% |
| Sale of Property, Plant, and Equipment | 40.00% | -73.68% | 58.33% | 33.33% | 28.57% |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -183.41% | 547.99% | -791.27% | 97.73% | -232.78% |
| Cash from Investing | -392.19% | 148.02% | 35.20% | -26.51% | -488.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 11.11% | 12.90% | 0.00% | -19.23% | 0.00% |
| Issuance of Common Stock | -43.37% | 844.78% | -44.07% | -46.26% | -3.14% |
| Repurchase of Common Stock | 10.45% | -521.77% | -101.19% | 76.58% | 60.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -9.68% | -399.35% | -1,009.90% | 106.50% | 71.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -269.91% | 838.10% | 144.57% | 75.16% | -221.29% |